Cognyxx Pharmaceuticals

Company Overview

Snapshot

Founded in June 2018 by Jacob George and Mike Fassler, Cognyxx Pharmaceuticals operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on research and development for its therapeutic solutions.

Business overview

Cognyxx Pharmaceuticals is a Health Tech & Life Sciences company developing solutions to enhance the immune system for treating cardiovascular and neurodegenerative disorders. The company's core technology aims to empower the body's natural defenses to combat these conditions. It operates within the Pharma & Medical Biotechnology sector, targeting healthcare providers in the broader healthcare and life sciences markets.

Company Intelligence Q&A

What is Cognyxx Pharmaceuticals' primary focus?

Cognyxx Pharmaceuticals is focused on developing treatments for cardiovascular and neurodegenerative disorders by empowering the immune system.

When was Cognyxx Pharmaceuticals founded?

Cognyxx Pharmaceuticals was founded in June 2018.

Who are the co-founders of Cognyxx Pharmaceuticals?

The co-founders of Cognyxx Pharmaceuticals are Jacob George and Mike Fassler.

What is the current product stage of Cognyxx Pharmaceuticals?

Cognyxx Pharmaceuticals is currently in the R&D product stage, actively working on developing its therapeutic solutions for cardiovascular and neurodegenerative disorders.

In which sector does Cognyxx Pharmaceuticals primarily operate?

Cognyxx Pharmaceuticals primarily operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology.